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Abstract
Background: We present the first case of Morvan’s syndrome (MoS) and myasthenia gravis (MG) related to familial
Mediterranean fever (FMF) gene mutations.
Case presentation: A 40-year-old woman with a 1-year history of bilateral ptosis and limb muscle weakness
presented to our hospital. She also had memory impairment, insomnia, hyperhidrosis, and muscle twitches.
Electromyography confirmed widespread myokymia, and there was evidence of temporal region dysfunction on
electroencephalography. Anti-voltage-gated potassium channel complex antibodies and anti-acetylcholine receptor
antibodies were both positive. Edrophonium administration was effective for bilateral ptosis and muscle weakness.
She and her family experienced self-limiting febrile attacks with arthralgia, which led us to suspect FMF. Genetic
analyses revealed compound heterozygous mutations in exon 2 of the MEFV gene (L110P/E148Q). From these
findings, a diagnosis of MoS and MG complicated with MEFV gene mutations was made. Intravenous high-dose
corticosteroids, plasma exchange, and intravenous immunoglobulin resulted in only transient, limited improvement,
and frequent relapses, especially in the myasthenic symptoms. Interleukin (IL)-6, IL-1β, and tumor necrosis factor-α
were markedly elevated in the serum, which was considered to be derived from the MEFV mutations and
responsible for the resistance to immunotherapy.
Conclusion: The present case illustrates a possible link between auto-inflammation and auto-antibody-mediated
neurological diseases.
Keywords: Morvan’s syndrome, Myasthenia gravis, Anti-voltage-gated potassium channel complex antibodies,
Myokymia, Familial Mediterranean fever
Background
Familial Mediterranean fever (FMF) is a genetic auto-
inflammatory disease characterized by self-limiting relapsing
fever and polyserositis, caused by mutations of the MEFV
gene encoding pyrin [1]. Some neurological autoimmune or
auto-inflammatory disorders, such as multiple sclerosis,
Behçet disease, and polymyositis (PM), have been reported
as complications of FMF [2, 3]. We report the first case of
Morvan’s syndrome (MoS) and myasthenia gravis (MG) re-
lated to FMF harboringMEFVmutations (L110P/E148Q).
Case presentation
A 40-year-old woman had experienced ptosis and double
vision with daily fluctuations for 1 year and was admit-
ted to our hospital in August 2012. She also had insom-
nia, hyperhidrosis, and progressive weakness of the
extremities. She had experienced recurrent fever, arthral-
gia, abdominal pain, and oral aphtha since childhood;
her mother, older sister, and son also had self-limiting
periodic fever. Neurologically, she had ptosis, double
vision, mild dysphagia, neck flexor weakness (Medical
Research Council (MRC) scale grade 4), symmetrical
weakness of her deltoids (MRC grades: right 4/left 4), tri-
ceps (right 4/left 4), digit flexors (right 3/left 3), quadriceps
(right 4/left 4), and tibialis anterior muscles (right 4/left
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4), grip myotonia, and myokymia. Myokymia was most
frequently seen in the bilateral first dorsal interosseous
muscles and less frequently in the lower leg and trunk
muscles. An edrophonium test was positive for ptosis,
double vision, and proximal limb muscle weakness but
not distal muscle weakness. Blood tests were unremark-
able except for hyper-IgDemia (12.2 mg/dL; normal,
0.0–9.0). Anti-acetylcholine receptor antibodies were
weakly positive (0.4 nmol/L; normal, <0.2) and anti-
muscle-specific receptor tyrosine kinase and anti-low dens-
ity lipoprotein receptor-related protein 4 antibodies were
negative. Anti-voltage-gated potassium channel (VGKC)
complex antibodies were elevated to 316 pM (normal,
<100), while antibodies against leucine-rich glioma inacti-
vated protein 1 (LGI1) and contactin-associated protein-
like 2 (Caspr2) were negative. Cerebrospinal fluid tests
including IgG index (0.51; normal, <0.73) were normal and
oligoclonal IgG bands were absent. Brain and skeletal
muscle magnetic resonance imaging and positron emission
tomography/computed tomography of the whole body
detected no abnormalities including thymic tumors. Needle
electromyography showed neuromyotonic discharges in the
left quadriceps and first dorsal interosseous muscles (Fig. 1a)
and myokymic discharges in the right thenar muscles
(Fig. 1b). Nerve conduction studies in the upper and lower
extremities were normal. Repetitive nerve stimulation of
the orbicularis oculi, frontalis, and abductor digiti minimi
muscles showed no decremental or incremental responses.
Electroencephalography revealed intermittent irregular slow
waves around 4 Hz in the left temporal region without epi-
leptic discharge. Unrelated word pairs (in Miyake’s Paired-
Associate Word Learning Test; a Japanese memory func-
tion test) elicited low scores: first task = 0 (normal, 3.2–7.0),
second task = 4 (normal, 6.6–10.0), and third task = 7 (nor-
mal, 7.7–10.0). Based on these observations, we diagnosed
her as having MoS complicated with MG. Intravenous
methylprednisolone (IVMP) (1 g/day for 3 days) followed
by oral prednisolone (PSL) (40 mg/day) with gradual
tapering and five courses of simple plasma exchange (PE)
alleviated the ptosis, double vision, memory disturbance,
hyperhidrosis, and insomnia. The left temporal slow waves
were diminished on electroencephalography. The unre-
lated word pair scores also improved: first task = 3, second
task = 9, and third task = 9. However, her myokymia and
Fig. 1 Clinical and pathological findings in the present case. a, b Needle electromyography at rest shows neuromyotonic discharges around
450 Hz in the left first dorsal interosseous muscle (a) and myokymic discharges in the right thenar muscle (b). The black arrow in a indicates an
insertional activity. c, d Analyses of MEFV gene mutations identified the heterozygous mutation L110P (c) and homozygous mutation E148Q (d)
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muscle weakness persisted. Administration of a choline
esterase inhibitor (pyridostigmine 180 mg/day) was effect-
ive for the ptosis, double vision, and proximal limb weak-
ness but not the distal muscle weakness. Genetic analyses
of MEFV revealed compound heterozygous mutations of
L110P/E148Q in exon 2 (Fig. 1c, d), while analyses for
mutations associated with tumor necrosis factor (TNF)
receptor-associated periodic syndrome and hyper-IgD
syndrome were negative. She had an HLA-B51/-52
genotype. Based on these findings, she was also diagnosed
with FMF [1].
Her MG symptoms were exacerbated in January 2013
and she was re-admitted to our hospital. Marked elevation
of serum interleukin (IL)-6 (353 pg/mL; normal, <8), TNF-
α (43 pg/mL; normal, <2.8), and IL-1β (24 pg/mL; normal,
<10) was found. She was treated with IVMP followed by
oral PSL (40 mg/day) with gradual tapering, which led to
limited efficacy for the ptosis and double vision. Although
oral colchicine (1 mg/day) resolved her recurrent fever,
arthralgia, and oral aphtha, her MG symptoms frequently
recurred from July 2013 to October 2014. PE and IVIg
(0.4 g/kg/day for 5 days) were required repeatedly every
several months, in addition to PSL (5–10 mg/day) and
immunosuppressants (tacrolimus 6 mg/day or azathioprine
100 mg/day), which showed transient efficacy for the ptosis,
double vision, and proximal limb weakness. However, the
limb weakness with myokymia progressively worsened
(right 3/left 3), which rendered her wheelchair-bound.
Discussion
FMF causes episodic rises in IL-1β and downstream pro-
inflammatory cytokines, such as IL-6 and TNF-α, with
recurrent fever and serosal inflammation [4]. Indeed,
serum IL-1β, TNF-α, and IL-6 were elevated in our
patient. Pyrin plays a critical role in assembly of the
inflammasome. Although it remains unclear how mu-
tated pyrin produces increases in IL-1β, hyper-activated
T helper (Th)1 and Th17 cells are assumed to contribute
to the auto-inflammatory response [4].
Interestingly, our patient developed MoS and MG, both
antibody-mediated diseases, but her myokymia and MG
symptoms were resistant to intensive immunotherapies. A
previous report described a case of FMF caused by MEFV
gene mutations of L110P and E148Q that coexisted with
PM [2]. In that case, colchicine treatment successfully
alleviated both FMF and PM, suggesting that the disease
activity of PM was considerably modulated by the coexisting
FMF [2]. Among the pro-inflammatory cytokines elevated
in our patient’s serum, IL-6 facilitates Th17 differentiation
from naïve T cells and decreases regulatory T cells. Further-
more, pathogenic Th17 cells were shown to exacerbate
experimental autoimmune MG [5]. Therefore, frequent pro-
inflammatory cytokine surges caused by the MEFV muta-
tions, despite their treatment by immunotherapies such as
PE, may be responsible for the refractory nature of MG, and
possibly MoS, in our case. However, for the development
of antibody-mediated neurologic diseases, activation of
the adaptive immune system is required, even in patients
with non-antigen-specific activation of the innate immune
system through a genetic disorder [6].
The reason for the involvement of the distal muscles
in our case is unclear. However, one explanation might
be that the myokymia and neuromyotonia, which reflect
peripheral nerve hyperexcitability (PNH), may play a
considerable role because PNH is a potential cause of
axon loss that can precede weakness or muscle atrophy
[7, 8]. Another explanation could be that the distal
muscle weakness was derived from MG because some
patients with MG can show distal muscle involvement
without other concomitant diseases that contribute to
distal muscle weakness [9]; however, a choline esterase
inhibitor was only effective for the proximal muscle
weakness, and not the distal muscle weakness, in our
patient.
Conclusions
In conclusion, FMF-related auto-inflammation may
contribute to the development and augmentation of
MG and MoS, suggesting a possible link between
auto-inflammation and auto-antibody-mediated diseases.
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